Facebook Pixel Code

Wockhardt Q4 net plummets 78 per cent to Rs 74 crore

Wockhardt had posted a net profit of Rs 334.76 crore in the corresponding period…

Wockhardt?s fourth-quarter profit continued to suffer from the impact of the US Food and Drug Administration-mandated import alerts on two of its production units. The company’s sales fell 30% year-on-year (y-o-y) while profit plunged nearly 78%.

The company reported net sales of Rs 1,038.7 crore while its net profit for the quarter ended March 31 was Rs 74.45 crore.

Analysts expected the company to report a profit of Rs 1165.1 crore, according to a poll by Bloomberg.

The company, whose sales to the United Kingdom have been constrained because of the limitation imposed by the country’s

regulatory watchdog, Medicines and Healthcare products Regulatory Agency (UKMHRA), said international business contributed 79% of the total revenues during FY14.

Financial year 2014 has been a trying period for the Habil Khorakiwala-led company, with its Waluj

and Chikalthana production units in Maharashtra under the regulatory lens for violation of manufacturing standards.

The manufacturing permit awarded to another manufacturing facility, Kadaiya located in Daman, was also pulled by the UKMHRA for the same reason. The company said its US business, which contributes 45% to Wockhardt’s topline, declined 26% to FY14.

Its UK business business recorded a growth of 3% in FY14. Its India business grew by 2% in FY14, while emerging markets? business, including India, fell 3% in the year.

Get live Share Market updates, Stock Market Quotes, and the latest India News and business news on Financial Express. Download the Financial Express App for the latest finance news.

First published on: 26-05-2014 at 20:10 IST
Market Data
Market Data
Today’s Most Popular Stories ×